AGRX — Agile Therapeutics Balance Sheet
0.000.00%
- $10.43m
- $7.58m
- $19.59m
- 48
- 46
- 70
- 54
Annual balance sheet for Agile Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 34.5 | 54.5 | 19.1 | 5.25 | 2.56 |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | 0.865 | 1.53 | 3.38 | 3.39 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 35.3 | 56.8 | 23.9 | 11.4 | 9.53 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 14.2 | 14.4 | 13.4 | 0.872 | 0.487 |
Other Long Term Assets | |||||
Total Assets | 49.5 | 73.1 | 39.3 | 14.2 | 10.3 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Current Liabilities | 3.79 | 7.35 | 29.3 | 13.4 | 20.8 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 3.79 | 23.7 | 30.1 | 19.8 | 26.6 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 45.7 | 49.3 | 9.27 | -5.54 | -16.3 |
Total Liabilities & Shareholders' Equity | 49.5 | 73.1 | 39.3 | 14.2 | 10.3 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |